[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-covid-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-covid-symptoms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,59,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":5},"100651314","epigenetic-changes-in-long-covid-patients-100651314",false,"NCT07757620","Epigenetic Changes in Long COVID Patients","Epigenetic Changes in Long COVID Patients: Unraveling the Gut-Immune Axis and Therapeutic Targets","ECLIPSE","Inclusion Criteria (Post COVID-19 patients):\n\n* Age ≥ 18 years.\n* Previous SARS-CoV-2 infection documented by molecular or serological testing.\n* Absence of persistent symptoms 2 months after acute infection.\n* Willingness to provide written informed consent.\n\nInclusion Criteria (Long COVID-19 patients):\n\n* Age ≥ 18 years.\n* Previous SARS-CoV-2 infection documented by molecular or serological testing.\n* Persistent symptoms at least 2 months after acute infection, according to the WHO definition of long COVID \\[https:\u002F\u002Fwww.who.int\u002Feurope\u002Fnews-room\u002Ffact-sheets\u002Fitem\u002Fpost-covid-19-condition\\].\n* Willingness to provide written informed consent.\n\nInclusion Criteria (Control Group):\n\n* Age ≥ 18 years.\n* No previous SARS-CoV-2 infection (documented by serology).\n* Blood sample collected according to the COVID-BioVac protocol (NCT05276388) before the first administration of the SARS-CoV-2 vaccine.\n* Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Presence of severe systemic autoimmune diseases or congenital\u002Facquired immunodeficiencies that may confound the interpretation of immunological data.\n* Current systemic immunosuppressive therapy or treatment within the last 6 months prior to enrollment.\n* Active malignancies or those treated within the last 12 months (except basal or squamous cell carcinomas in situ).\n* Pregnancy or breastfeeding at the time of enrollment.\n* Any other clinical condition that, in the investigator's opinion, could compromise the reliability of the data collected.",true,"ALL","18 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to improve the understanding of the biological mechanisms underlying long COVID and to identify molecular biomarkers that may support its diagnosis, prognosis, and future precision medicine approaches in adults with long COVID, adults who have fully recovered from COVID-19, and healthy control participants.\n\nThe main questions it aims to answer are:\n\n* What molecular, immunological, epigenetic, and microbiome profiles distinguish individuals with long COVID from recovered COVID-19 participants and healthy controls?\n* How are viral persistence, immune dysregulation, and alterations in the gut-immune axis associated with the development and clinical manifestations of long COVID?\n* Which molecular biomarkers may improve disease diagnosis, patient stratification, and the identification of potential therapeutic targets?\n\nParticipants will:\n\n* Undergo clinical evaluation and provide information about their medical history and symptoms.\n* Provide biological samples, including blood and, when clinically indicated, intestinal biopsy tissue collected during routine colonoscopy procedures.\n* Undergo comprehensive molecular analyses, including immunological, epigenetic, transcriptomic, proteomic, and microbiome profiling.\n* Have their clinical and molecular data integrated using advanced computational approaches to identify biological signatures associated with long COVID.\n\nThe results of this study may improve the understanding of the biological mechanisms underlying long COVID and support the development of novel biomarkers and future precision medicine approaches for diagnosis, prognosis, patient stratification, and therapeutic target identification.",[26,27],"Long COVID-19 Syndrome","Long COVID Symptoms",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Long COVID-19","COVID-19","gut","Chronic inflammation","epigenetics","methylation","omics","artificial intelligence","ai","machine learning","Multi-omics approaches","biomarker","Immune aging","genomics","transcriptomics","spatial omics","epigenomics","cytokines","NOT_YET_RECRUITING","2026-08-05",{"date":50,"type":51},"2026-08-11","ACTUAL",{"date":53,"type":22},"2026-09",{"date":55,"type":22},"2027-12",{"name":57,"class":58},"Istituti Clinici Scientifici Maugeri SpA","OTHER",{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100646276","a-pilot-randomized-controlled-trial-of-homeopathic-treatment-for-long-covid-100646276","NCT07694232","A Pilot Randomized Controlled Trial of Homeopathic Treatment for Long COVID","long COVID POD","Inclusion Criteria:\n\n* Adults who experienced acute COVID-19 at least 12 weeks ago\n* A medical diagnosis of long COVID (diagnosis by a healthcare professional, documentation from an NHS long COVID clinic, or equivalent formal medical verification)\n* At least one recognized long COVID symptom according to NHS criteria\n* Agreement to be contacted again and interest in participating in research.\n\nExclusion Criteria:\n\n* Those who have not had acute COVID-19\n* Those who have not received a medical diagnosis of long COVID\n* Those not currently experiencing symptoms (MYMOP average score 1 or less)\n* Inability to give informed consent\n* Inability to complete online forms and receive zoom calls\n* Those currently under homeopathic treatment\n* Those who have started a new medication or treatment for long COVID within the past month\n* Those suffering from life threatening conditions",{"count":67,"type":22},120,"INTERVENTIONAL",[70],"NA","A small-scale test of the intervention, trial design and methods to explore the cumulative effectiveness of two commonly used prescribing strategies for patients with long COVID: Treatment A - prescribing a specific homeopathic remedy for long COVID, plus or minus Treatment B - a course of individually tailored treatment by a homeopath. Both interventions compared to usual care",[73,27],"Long COVID",[75,76,77],"homeopathy","long COVID","randomised controlled trial","2026-07-02",{"date":80,"type":51},"2026-07-09",{"date":82,"type":22},"2026-07-15",{"date":84,"type":22},"2028-12-01",{"name":86,"class":58},"St. Mary's University, Twickenham",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":96,"targetDuration":98,"studyType":23,"phases":4,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":87},"100625018","persistent-covid-19-registry-in-navarre-100625018","NCT07417176","Persistent COVID-19 Registry in Navarre.","Persistent COVID-19 Registry in Navarre. (Persicov-19)","PERSICOV-19","Inclusion Criteria:\n\n* History of confirmed SARS-CoV-2 infection\n* Presentation of symptoms that have persisted for more than 3 months after SARS-CoV-2 infection\n* The patient reports any of the symptoms listed in the clinical assessment questionnaire or checklist.\n\nExclusion Criteria:\n\n* The symptom(s) referred to already existed prior to acute SARS-CoV-2 infection.",{"count":97,"type":22},200,"3 Months","The goal of this observational study is to deepen our understanding of long COVID by determining the prevalence of the main complications and medium- to long-term sequelae of COVID-19 in Navarre.\n\nSociodemographic variables such as age, sex, ethnicity, smoking history, and comorbidities will be collected, as well as clinical and disease management variables such as persistent COVID-19 symptoms at 3 months, all with the aim of characterizing patients with long COVID.\n\nAll patient data will be collected in a single visit.",[27,101],"Long COVI",[103,104,105],"long covid 19","Long COVID syndrome","Long COVID Fatigue","RECRUITING","2026-02-18",{"date":109,"type":51},"2026-02-20",{"date":111,"type":51},"2021-01-04",{"date":113,"type":22},"2026-03-31",{"name":115,"class":58},"Fundacion Miguel Servet"]